Acrux Limited (ARUXF)

OTCMKTS · Delayed Price · Currency is USD

0.0033

-0.0136 (-80.47%)

At close: Aug 11, 2026

Market Cap	4.65M +15.6%
Revenue (ttm)	4.55M +46.6%
Net Income	-417.85K
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,080
Open	0.0252
Previous Close	0.0169
Day's Range	0.0033 - 0.0252
52-Week Range	0.0010 - 0.0504
Beta	0.97
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Acrux

Acrux Limited, together with its subsidiaries, develops and commercializes topically applied pharmaceutical products in Australia, the United States, Europe, and internationally. The company offers Dapsone 7.5% and 5% gels for the treatment of acne vulgaris; Nitroglycerine 0.4% ointments for the treatment of moderate to severe pain associated with chronic anal fissure; Lidocaine and Prilocaine creams USP 2.5% for local analgesia and pre-treatment for infiltration anesthesia; and estradiol transdermal sprays for women for the treatment of modera... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1998

Employees 43

Stock Exchange OTCMKTS

Ticker Symbol ARUXF

Financial Performance

In fiscal year 2026, Acrux's revenue was 6.58 million, an increase of 46.64% compared to the previous year's 4.49 million. Losses were -604,000, -89.84% less than in 2025.

Financial numbers in AUD Financial Statements